HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cancer vaccines: can they improve survival?

Abstract
In patients with metastatic cancer, therapeutic anticancer vaccines are rarely associated with objective antitumor responses; so, many investigators have focused on progression-free survival (PFS) as a key endpoint for clinical trials. However, it is not clear that PFS is a surrogate for overall survival (OS), and OS may be a more appropriate endpoint because of the effects on long-term memory in the adaptive immune system. Recently, reported vaccine trials were reviewed to determine their primary and secondary endpoints and results. Randomized trials testing sipuleucel-T and prostvac-vf in prostate cancer and ipilimumab and eltrapuldencel-T in melanoma were associated with low objective response rates, no improvement in PFS, but statistically significant improvement in OS. Although compared with PFS, it takes longer to get a final result when OS is the primary endpoint; there is increasing evidence that if long-term memory recognition of tumor-associated antigens is the mechanism of action of an investigational product, then OS may be the only valid clinical endpoint for efficacy.
AuthorsRobert O Dillman
JournalCancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 30 Issue 4 Pg. 147-51 (May 2015) ISSN: 1557-8852 [Electronic] United States
PMID25747158 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Ipilimumab
  • PROSTVAC
  • Tissue Extracts
  • sipuleucel-T
Topics
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antigens, Neoplasm (immunology)
  • Cancer Vaccines (immunology, therapeutic use)
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Disease-Free Survival
  • Humans
  • Ipilimumab
  • Male
  • Melanoma (drug therapy, immunology)
  • Prostatic Neoplasms (drug therapy, immunology)
  • Randomized Controlled Trials as Topic
  • Tissue Extracts (immunology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: